News

Investing.com -- Eli Lilly and Company announced additional positive results today from pivotal Phase 3 trials of its investigational weight loss drug, retatrutide. The data, presented at the American Diabetes Association Scientific Sessions, positions the triple hormone receptor agonist as a potential next-generation successor to current dual-agonist therapies like tirzepatide. In the 80-week TRIUMPH-1 trial evaluating adults with obesity, participants taking a 12 mg dose of retatrutide lost an

Eli Lilly just announced a trio of acquisitions that will allow it to build a new business focused on infectious diseases.

For investors wondering if Eli Lilly's share price still makes sense after such strong gains, or if expectations have run ahead of reality, this article focuses squarely on what you are paying versus what you may be getting. The stock last closed at US$1,131.42, with returns of 2.4% over 7 days, 14.6% over 30 days, 4.7% year to date and 48.0% over the past year, alongside a very large 3-year return and around 5x over 5 years. Recent market attention on Eli Lilly has largely centered on its...

Sen. Elizabeth Warren (D-Mass.) criticized President Donald Trump’s trading activity, arguing that the volume and timing of transactions in his investment portfolio raised questions about potential conflicts of interest and reinforced the need to ban government officials from trading on...

Eli Lilly and Company (NYSE:LLY) was among the stocks on which Jim Cramer gave his opinion, as he warned that increased AI-related spending might cause near-term headwind for stocks. Cramer noted that the company’s GLP-1 franchise is the best, as he said: CEO David Ricks is a terrific steward of his shareholders’ capital. Still, at […]

International growth could help push Lilly even higher.

Investing.com -- Pfizer Inc (NYSE:PFE) has unveiled detailed strategy plans and clinical data for its experimental weight-loss injection, aiming to secure a foothold in a competitive market currently dominated by rivals. The New York-based pharmaceutical giant is working to catch up to industry leaders Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO), which have captured significant market share through their first-mover advantages. Following earlier clinical setbacks, Pfizer rev

Investors appear to have left Novo Nordisk behind as they focus on Eli Lilly; that could be a mistake.

Eli Lilly leads three health care stocks to watch as the market appears to be rotating into medicals. Google stock is finding key support too.

Eli Lilly (NYSE:LLY) is pushing beyond its obesity drug franchise with plans to acquire three vaccine focused biotech companies. The company has also entered new collaborations in genetic and RNA based therapies with partners including Ascidian Therapeutics, Hanmi Pharm, and Haisco Pharmaceutical Group. These moves come alongside broader offerings on LillyDirect, signaling a wider repositioning of its product pipeline. Eli Lilly, trading at $1,131.42, has seen very large share price gains...

The market rally broke key support; here's what to do. The SpaceX IPO, Apple's AI push and Oracle earnings loom.

Healthcare stocks gain traction as investors rotate away from volatile AI and technology names.

Both drugmakers are expanding internationally as pricing and access remain major barriers.

TD Cowen raises its 2030 GLP-1 sales forecast as Lilly and Novo are expected to keep dominant market shares.

Eli Lilly and Company (NYSE:LLY) is one of the 10 Best American Stocks to Buy and Hold for the Next Decade. On May 31, 2026, Eli Lilly and Company (NYSE:LLY) announced results from the Phase 3 Libretto-432 clinical trial of Retevmo as adjuvant therapy versus placebo in patients with early-stage rearranged during transfection fusion-positive non-small […]

The seasonal strength lines up with major medical and scientific conferences that cluster during this period.

Johnson & Johnson (NYSE:JNJ) was among Jim Cramer’s stock calls on Mad Money, as he highlighted several opportunities in out-of-favor sectors. Cramer highlighted the company’s billion-dollar drugs and growing businesses, as he stated: So I’m going to do something completely out of favor and recommend one that we’re buying for the Charitable Trust gingerly, as […]

Eli Lilly and Company (NYSE:LLY) was among Jim Cramer’s stock calls on Mad Money, as he highlighted several opportunities in out-of-favor sectors. Cramer mentioned the stock while discussing the woes of the healthcare industry, as he said: Next worst is healthcare. Oh, this group has just been annihilated. I’ve never seen it trading this bad […]

LLY's 2026 deal-making spree spans vaccines, oncology and neuroscience, aiming to diversify growth beyond GLP-1s amid rising obesity competition.

Eli Lilly stock gains 14% in a month as strong Q1 results, obesity drug coverage expansion and promising retatrutide data fueled momentum.

TD Cowen expects around 59 million patients worldwide to be using GLP-1 therapies by the end of the decade, up sharply from its previous estimate of 46 million.

In late May and early June 2026, Eli Lilly reported strong Phase 3 results for obesity, diabetes and oncology drugs, broadened coverage of its full obesity portfolio by all three major U.S. pharmacy benefit managers, and added Sesame and WW International’s Weight Watchers Med+ programs to its LillyDirect digital platform to improve access and support for patients. Together, these developments deepen Lilly’s presence across the entire cardiometabolic care journey, from gene-editing and...

It's another step in Eli Lilly's quest to cement its lead in the chronic weight management market.

From hepatitis B to melanoma, recent study results show innovative approaches are gaining ground.

BRK.B, LLY and WMT headline top analyst reports, highlighting business strengths, growth drivers and key risks shaping their outlooks.

Competition is intensifying after WeightWatchers' Med+ program became available through LillyDirect.

Shares of personal wellness company WeightWatchers (NASDAQ:WW) jumped 6.3% in the afternoon session after the company announced its Weight Watchers Med+ program is now accessible through Eli Lilly's digital healthcare platform, LillyDirect.

Eli Lilly reported positive Phase 1b data for VERVE-102, a gene-editing cardiovascular therapy, raising fresh competitive pressure on CRISPR Therapeutics' CTX310 program. CRISPR Therapeutics (NasdaqGM:CRSP) is broadening beyond gene editing with the acquisition of CTX611, a phase 2 siRNA therapy targeting blood clotting. These developments arrive as large pharma and specialist biotech companies increase focus on genetic and RNA-based approaches to cardiovascular disease. For you as an...

Biopharma M&A has surged to $106 billion across 201 deals through early June 2026, putting the sector on track for its strongest full-year total since the 2019 pre-pandemic peak, CNBC reported.

Dow Jones futures fell slightly after hours, along with S&P 500 futures and Nasdaq futures. The May jobs report is on tap before Friday's open. The stock market saw the Dow Jones jump to a record high, aided by lower oil prices and Treasury yields.